flowchart LR
subgraph GLP1["GLP-1"]
direction TB
g1["GLP-1"] --> d1["δ-cells<br/>somatostatin↑"]
g1 --> b1["β-cells<br/>insulin↑"]
d1 -->|"inhibits"| a1["α-cells<br/>glucagon↓"]
b1 -->|"inhibits"| a1
end
subgraph GIP["GIP"]
direction TB
g2["GIP"] --> a2["α-cells (many GIPR)<br/>glucagon↑"]
g2 --> b2["β-cells<br/>insulin↑"]
end
4 Actions in the Islets: β-Cells and α-Cells
The pancreatic islets (islets of Langerhans) contain β-cells that release insulin, α-cells that release glucagon, δ-cells that release somatostatin, and others, and these cells influence one another (paracrine regulation). GLP-1 and GIP act on all three cell types.
4.1 β-cells: insulin secretion
As seen in Chapter 3, both GLP-1 and GIP enhance insulin secretion in a glucose-dependent manner. Besides acute stimulation of secretion, they have the following actions.
| Action | GLP-1 | GIP | Notes |
|---|---|---|---|
| Enhanced insulin secretion (glucose-dependent) | ◎ | ◎ | Response to GIP is reduced in type 2 diabetes |
| Insulin biosynthesis (gene transcription, translation)↑ | ◎ | ○ | Replenishes stores depleted by secretion |
| β-cell proliferation, suppression of apoptosis | ○ | ○ | Mainly rodent data. An increase in β-cell mass has not been confirmed in adult humans |
You often hear that “GLP-1 increases β-cells”, but much of the evidence comes from experiments in young rodents. Adult human β-cells have very low proliferative capacity, and an increase in β-cell mass with GLP-1RAs has not been shown in humans. The improvement in β-cell function seen clinically is thought to be mainly due to relief of the burden of hyperglycemia (glucotoxicity) and functional improvement.
4.2 α-cells: here GLP-1 and GIP are opposite
One of the biggest differences between GLP-1 and GIP is their action on glucagon.
| GLP-1 | GIP | |
|---|---|---|
| Glucagon secretion | Suppressed (during hyperglycemia) | Stimulated (especially at low-to-normal glucose) |
| Receptors on α-cells | Few (mainly indirect action) | Many (direct action) |
4.2.1 Glucagon suppression by GLP-1
Because α-cells express almost no GLP-1R, GLP-1’s suppression of glucagon is mainly indirect.
- GLP-1R on δ-cells → somatostatin secretion↑ → inhibits α-cells
- Inhibition by insulin, zinc, etc. from β-cells
This suppression is also glucose-dependent and does not interfere with glucagon secretion during hypoglycemia (a response essential for recovery from hypoglycemia).
4.2.2 Glucagon stimulation by GIP: why would it do that?
You may think, “Isn’t it contradictory to release glucagon when we want to lower blood glucose?” Physiologically, it can be understood as follows.
- During hyperglycemia: GIP strongly promotes insulin secretion (its glucagon-stimulating action is inconspicuous)
- At low-to-normal glucose: GIP releases little insulin and instead releases glucagon
- With a meal centered on fat and protein (a low-carbohydrate meal), releasing only insulin could cause hypoglycemia. Releasing glucagon at the same time stabilizes blood glucose — this is thought to be the purpose
In other words, GIP can be regarded as a “bidirectional glucose-stabilizing hormone” that adjusts the balance between insulin and glucagon according to the blood glucose level.
In type 2 diabetes, the insulinotropic action of GIP weakens while its glucagon-stimulating action remains. Therefore, physiological GIP may act in the direction of worsening hyperglycemia in type 2 diabetes, which is one of the reasons it was long thought that “GIP can’t be made into a drug”.
4.3 Looking at the islet as a whole
flowchart LR Meal["After a meal<br/>blood glucose↑"] --> Inc["GLP-1 / GIP↑"] Inc --> Ins["Insulin↑"] Inc --> GlcgN["Glucagon<br/>GLP-1: ↓ / GIP: depends on glucose"] Ins --> Liver["Liver<br/>gluconeogenesis, glycogenolysis↓"] GlcgN --> Liver Ins --> Muscle["Muscle, fat<br/>glucose uptake↑"] Liver --> BG["Curbs the postprandial rise in blood glucose"] Muscle --> BG
Lowering blood glucose is not just about “increasing insulin”; “reducing glucagon to suppress glucose output from the liver” is equally important. A substantial part of the glucose-lowering effect of GLP-1RAs is thought to be due to this glucagon suppression.
4.4 Summary
- β-cells: both GLP-1 and GIP increase insulin secretion in a glucose-dependent manner and increase insulin biosynthesis
- α-cells: GLP-1 lowers glucagon (indirect action via δ-cells and β-cells), GIP raises glucagon (direct action, especially during hypoglycemia)
- GIP is a “bidirectional” hormone that uses insulin and glucagon selectively according to the blood glucose level
- The β-cell proliferative action is mainly rodent data and has not been confirmed in adult humans